Gilead Sciences, Inc. [NASDAQ: GILD] stock went on a downward path that fall over -0.27% on Monday, amounting to a one-week price increase of more than 2.86%.
Over the last 12 months, GILD stock rose by 13.07%. The one-year Gilead Sciences, Inc. stock forecast points to a potential downside of -0.67. The average equity rating for GILD stock is currently 1.97, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $110.51 billion, with 1.25 billion shares outstanding and 1.24 billion shares in the current float. Compared to the average trading volume of 6.12M shares, GILD stock reached a trading volume of 5960416 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Gilead Sciences, Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $88.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 1.97. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Gilead Sciences, Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on October 21, 2024. While these analysts kept the previous recommendation, Bernstein raised their target price to Outperform. The new note on the price target was released on October 17, 2024, representing the official price target for Gilead Sciences, Inc. stock. Previously, the target price had yet another raise from $78 to $100, while Wells Fargo kept a Overweight rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences, Inc. is set at 1.42, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.98. The Price to Book ratio for the last quarter was 6.05, with the Price to Cash per share for the same quarter was set at 3.37. Price to Free Cash Flow for GILD in the course of the last twelve months was 16.02 with Quick ratio for the last quarter at 0.95.
GILD Stock Performance Analysis:
Gilead Sciences, Inc. [GILD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.86. With this latest performance, GILD shares gained by 6.16% in over the last four-week period, additionally plugging by 34.61% over the last 6 months – not to mention a rise of 13.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 68.00, with the RSI for the last a single of trading hit 68.14, and the three-weeks RSI is set at 67.68 for Gilead Sciences, Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 82.66, while it was recorded at 88.39 for the last single week of trading, and 74.13 for the last 200 days.
Insight into Gilead Sciences, Inc. Fundamentals:
Gilead Sciences, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.95 and a Current Ratio set at 1.14.
GILD Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc. go to 6.29%.
Gilead Sciences, Inc. [GILD] Institutonal Ownership Details
There are presently around $87.92%, or 88.03%% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 120.63 million shares, which is approximately 9.6738%. VANGUARD GROUP INC, holding 115.26 million shares of the stock with an approximate value of $$7.91 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $$5.23 billion in GILD stock with ownership which is approximately 6.1147%.
